On February 4 2026, Qiagen announced that it will showcase its new QIAsprint Connect high‑throughput automation system at the SLAS 2026 conference in Boston. The platform can process up to 192 samples per run and features modular, sustainability‑focused consumables that reduce plastic waste and packaging volume, positioning the company to serve large‑batch research laboratories that demand flexible, scalable workflows.
QIAsprint Connect is the third tier in Qiagen’s tiered automation strategy, which also includes the low‑throughput QIAmini and the mid‑throughput QIAsymphony Connect. By covering the full throughput spectrum, Qiagen expands its “sample‑to‑insight” offering and strengthens its competitive position across all laboratory sizes.
The high‑throughput segment has historically been underserved by competitors, and QIAsprint Connect targets research labs that run large batches of assays. The system’s modular consumables and sustainability focus align with industry trends toward greener laboratory operations, giving Qiagen a differentiator in a growing market.
The launch is expected to generate recurring consumable revenue from high‑volume users, reinforcing Qiagen’s margin‑sustainable business model. The announcement coincided with the release of Qiagen’s Q4 2025 earnings on the same day, where analysts had estimated $0.61 earnings per share and $527.96 million in revenue, underscoring the company’s strong financial performance.
By adding QIAsprint Connect, Qiagen broadens its “sample‑to‑insight” portfolio, potentially capturing a new market segment and strengthening its competitive position across all throughput levels.
The system will be showcased on February 9 2026 at SLAS 2026, giving laboratories an opportunity to evaluate the platform’s capabilities in person.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.